Imtiaz Ahmed, MD
Allergy/ Immunology · Kissimmee, FLNPI 1922071158
Payments from drug & device makers
Across 220 payments — averaging $23.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$948
- AstraZeneca$490
- Regeneron Healthcare Solutions, Inc.$419
- Sanofi$402
- Pfizer$398
- Takeda Pharmaceuticals U.S.A., Inc.$356
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,12998%
- Education$1102%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 45 | $948 |
| AstraZeneca | 22 | $490 |
| Regeneron Healthcare Solutions, Inc. | 15 | $419 |
| Sanofi | 17 | $402 |
| Pfizer | 19 | $398 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $356 |
| Novartis | 12 | $301 |
| Biocryst US Sales Co., LLC | 8 | $237 |
| CSL Behring | 8 | $202 |
| Grifols USA, LLC | 9 | $195 |
| AbbVie | 8 | $189 |
| Genentech USA, Inc. | 8 | $167 |
| Merck | 1 | $157 |
| Pharming Healthcare, Inc. | 6 | $126 |
| Blueprint Medicines Corporation | 2 | $125 |
| Shire North American Group Inc | 4 | $82 |
| Octapharma USA, Inc. | 4 | $81 |
| Amgen(2 entities) | 3 | $76 |
| Teva Pharmaceuticals USA, Inc. | 4 | $71 |
| Incyte Corporation | 3 | $64 |
| Cycle Pharmaceuticals Inc | 1 | $29 |
| Ionis Pharmaceuticals, Inc. | 1 | $26 |
| Tersera Therapeutics LLC | 1 | $24 |
| Circassia Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$122
How this compares
Too few allergy/ immunology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrladeyoBerotralstat Hydrochloride | 20 | $813,116 |
| HaegardaC1 Esterase Inhibitor | 17 | $589,777 |
| Dupixent PenDupilumab | 99 | $396,462 |
| XolairOmalizumab | 152 | $393,667 |
| TezspireTezepelumab-Ekko | 25 | $104,828 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 102 | $86,704 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $65,600 |
| Fasenra PenBenralizumab | 11 | $59,924 |
| NucalaMepolizumab | 16 | $57,070 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $46,471 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 65 | $40,740 |
| Epinephrine | 52 | $11,751 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $11,668 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $10,237 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $4,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biocryst US Sales Co., LLCOrladeyo | $237 | $813,11620 claims |
| CSL BehringHaegarda | $202 | $589,77717 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $490 | $157,236130 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta | $948 | $154,011132 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $356 | $65,60013 claims |
| Grifols USA, LLCGamunex-C | $195 | $46,47113 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $11,75152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other allergy/ immunology in Kissimmee
- Michael AndersonOrlando$325K
- Jack ParrinoTampa$13K
- Julio PardaveHialeah$2K
- Robert MastrosimoneBoynton Beach$2K
- Roy KrochmalMiami$61
- Kimberly BlumenthalJacksonville$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.